Revathy Carnagarin

Dr Revathy Carnagarin is a Researcher at the UWA Medical School, University of Western Australia, specializing in hypertension and renal denervation research within the Department of Internal Medicine. Her work focuses on autonomic nervous system dysregulation in cardiovascular disease, with emphasis on resistant hypertension and novel interventional therapies.

Her research interests span hypertension pathophysiology, renal denervation outcomes, neuroinflammation in cardiovascular disease, and antihypertensive therapeutic strategies. Key areas include sympathetic nervous system modulation, blood pressure monitoring technologies, neuroimmune interactions, and cardiovascular risk stratification. Her fingerprint analysis reveals dominant expertise in Blood Pressure (100%), Kidney Denervation (66%), Antihypertensive Agents (37%), and Sympathetic Nervous System (37%).

Recent publications demonstrate a clear trajectory toward clinical translation of renal denervation techniques, with 2024-2025 studies examining long-term electrocardiographic changes, blood pressure gradients in aging populations, and predictive biomarkers for treatment response. Her meta-analysis on catheter-based renal denervation (31 Scopus citations) has significantly influenced clinical practice.

• National Heart Foundation Post doctoral fellowship (2020)
• National Heart Foundation Miles Award (2018)

Dr Carnagarin has secured six major research grants totaling over A$500,000, including the NHF Postdoctoral Fellowship (2020-2022) investigating immune mechanisms in hypertension and the Abbott-funded project on sympathoinhibition for obesity-related hypertension (2020-2024). She serves as principal investigator on multiple studies exploring neuroinflammation pathways and novel antihypertensive combinations. Her collaborative network spans 15+ international institutions with Prof Markus Schlaich as primary co-investigator.

Her research contributes directly to UN Sustainable Development Goal 3 (Good Health and Well-being) through innovations in hypertension management affecting global cardiovascular outcomes.